H.C. Wainwright Reiterates Buy Rating on Foghorn Therapeutics (FHTX)

April 22, 2026 6:41 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $13.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found